Bone Morphogenic Protein-7 (BMP7) und die Niere

Schlüsselwörter

chronische Niereninsuffizienz - Fibrose - Bone Morphogenic Protein

Keywords

chronic kidney disease - fibrosis - Bone Morphogenic Protein

Literatur

• 1 Bahlmann F H, Kielstein J T, Haller H, Fliser D. Erythropoietin and progression of CKD.  Kidney int. 2007;  Suppl S21-25
• 2 Bohle A, Christ H, Grund K E, Mackensen S. The role of the interstitium of the renal cortex in renal disease.  Contrib Nephrol. 1979;  16 109-114
• 3 Boor P, Sebekova K, Ostendorf T, Floege J. Treatment targets in renal fibrosis.  Nephrol Dial Transplant. 2007;  22 3391-3407
• 4 Border W A, Noble N A. Transforming growth factor beta in tissue fibrosis.  New Engl J Med. 1994;  331 1286-1292
• 5 Derynck R, Gelbart W M, Harland R M. et al . Nomenclature: vertebrate mediators of TGFbeta family signals.  Cell. 1996;  87 173
• 6 Dolan V, Murphy M, Sadlier D. et al . Expression of gremlin, a bone morphogenetic protein antagonist, in human diabetic nephropathy.  Am J Kidney Dis. 2005;  45 1034-1039
• 7 Dudley A T, Lyons K M, Robertson E J. A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye.  Genes & Development. 1995;  9 2795-2807
• 8 Eknoyan G, Lameire N, Barsoum R. et al . The burden of kidney disease: improving global outcomes.  Kidney int. 2004;  66 1310-1314
• 9 Floege J, Grone H J. Progression of renal failure: what is the role of cytokines?.  Nephrol Dial Transplant. 1995;  10 1575-1586
• 10 Hogan B L. Bone morphogenetic proteins in development.  Current Opinion Genet Development. 1996;  6 432-438
• 11 Hugo C. The thrombospondin 1-TGF-beta axis in fibrotic renal disease.  Nephrol Dial Transplant. 2003;  18 1241-1245
• 12 Kalluri R, Zeisberg M. Exploring the connection between chronic renal fibrosis and bone morphogenic protein-7.  Histol Histopathol. 2003;  18 217-224
• 13 Kazama I, Mahoney Z, Miner J H. et al . Podocyte-derived BMP7 is critical for nephron development.  J Am Soc Nephrol. 2008;  19 2181-2191
• 14 Lin J, Patel S R, Cheng X. et al . Kielin/chordin-like protein, a novel enhancer of BMP signaling, attenuates renal fibrotic disease.  Nat Med. 2005;  11 387-393
• 15 Luo G, Hofmann C, Bronckers A L. et al . BMP-7 is an inducer of nephrogenesis, and is also required for eye development and skeletal patterning.  Genes Development. 1995;  9 2808-2820
• 16 Maric I, Poljak L, Zoricic S. et al . Bone morphogenetic protein-7 reduces the severity of colon tissue damage and accelerates the healing of inflammatory bowel disease in rats.  J cell Physiol. 2003;  196 258-264
• 17 Ozkaynak E, Schnegelsberg P N, Oppermann H. Murine osteogenic protein (OP-1): high levels of mRNA in kidney.  Biochem Biophysical Res Commun. 1991;  179 116-123
• 18 Panzer U, Steinmetz O M, Stahl R A, Wolf G. Kidney diseases and chemokines.  Current Drug Targets. 2006;  7 65-80
• 19 Peters H, Border W A, Noble N A. Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade.  Kidney int. 1998;  54 1570-1580
• 20 Roxburgh S A, Kattla J J, Curran S P. et al . Allelic depletion of grem1 attenuates diabetic kidney disease.  Diabetes. 2009;  58 1641-1650
• 21 Sampath T K, Maliakal J C, Hauschka P V. et al . Recombinant human osteogenic protein-1 (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro.  J biolog Chem. 1992;  267 20 352-20 362
• 22 Schaefer L, Macakova K, Raslik I. et al . Absence of decorin adversely influences tubulointerstitial fibrosis of the obstructed kidney by enhanced apoptosis and increased inflammatory reaction.  Amer J Pathol. 2002;  160 1181-1191
• 23 Simon M, Maresh J G, Harris S E. et al . Expression of bone morphogenetic protein-7 mRNA in normal and ischemic adult rat kidney.  The American journal of physiology. 1999;  276 F382-389
• 24 Sterzel R B, Hartner A, Hilgers K F, Bressan G M. Contribution of the mesangium to elastic strength and anchorage of the glomerular capillary tuft.  Contribut Nephrol. 2001;  131 132-141
• 25 Strutz F, Muller G A. Interstitial pathomechanisms underlying progressive tubulointerstitial damage.  Kidney Blood Press Res. 1999;  22 71-80
• 26 Strutz F, Zeisberg M, Renziehausen A. et al . TGF-beta1 induces proliferation in human renal fibroblasts via induction of basic fibroblast growth factor (FGF-2).  Kidney international. 2001;  59 579-592
• 27 Sugimoto H, Grahovac G, Zeisberg M, Kalluri R. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors.  Diabetes. 2007;  56 1825-1833
• 28 Swencki-Underwood B, Mills J K, Vennarini J. et al . Expression and characterization of a human BMP-7 variant with improved biochemical properties.  Protein Expression Purification. 2008;  57 312-319
• 29 Tamaki K, Souchelnytskyi S, Itoh S. et al . Intracellular signaling of osteogenic protein-1 through Smad5 activation.  Journal of cellular physiology. 1998;  177 355-363
• 30 Tonelli M, Wiebe N, Culleton B. et al . Chronic kidney disease and mortality risk: a systematic review.  J Am Soc Nephrol. 2006;  17 2034-2047
• 31 Urist M R. Bone: formation by autoinduction.  Science. 1965;  150 893-899
• 32 Vukicevic S, Basic V, Rogic D. et al . Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat.  J clin invest. 1998;  102 202-214
• 33 Wang S, Chen Q, Simon T C. et al . Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy.  Kidney int. 2003;  63 2037-2049
• 34 Wang S N, Lapage J, Hirschberg R. Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy.  J Am Soc Nephrol. 2001;  12 2392-2399
• 35 Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications.  Kidney int. 2005;  67 799-812
• 36 Wolf G, Zahner G, Schroeder R, Stahl R A. Transforming growth factor beta mediates the angiotensin-II-induced stimulation of collagen type IV synthesis in cultured murine proximal tubular cells.  Nephrol Dial Transplant. 1996;  11 263-269
• 37 Yanagita M, Oka M, Watabe T. et al . USAG-1: a bone morphogenetic protein antagonist abundantly expressed in the kidney.  Biochem biophys Res Commun. 2004;  316 490-500
• 38 Zeisberg E M, Tarnavski O, Zeisberg M. et al . Endothelial-to-mesenchymal transition contributes to cardiac fibrosis.  Nat Med. 2007;  13 952-961
• 39 Zeisberg M, Bottiglio C, Kumar N. et al . Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models.  Am J Physiol Renal Physiol. 2003;  285 F1060-1067
• 40 Zeisberg M, Hanai J, Sugimoto H. et al . BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury.  Nat Med. 2003;  9 964-968
• 41 Zeisberg M, Kalluri R. Experimental strategies to reverse chronic renal disease.  Blood purification. 2004;  22 440-445
• 42 Zeisberg M, Kalluri R. The role of epithelial-to-mesenchymal transition in renal fibrosis.  J Mol Med. 2004;  82 175-181
• 43 Zeisberg M, Muller G A, Kalluri R. Are there endogenous molecules that protect kidneys from injury? The case for bone morphogenic protein-7 (BMP-7).  Nephrol Dial Transplant. 2004;  19 759-761
• 44 Zeisberg M, Strutz F, Muller G A. Renal fibrosis: an update.  Curr Opin Nephrol Hypertens. 2001;  10 315-320
• 45 Zeisberg M, Yang C, Martino M. et al . Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition.  J biol Chem. 2007;  282 23337-23347
• 46 Zeisberg M. Bone morphogenic protein-7 and the kidney: current concepts and open questions.  Nephrol Dial Transplant. 2006;  21 568-573